‘Capture the high-priced private market’… Premium vaccine competition outside of NIP

‘Capture the high-priced private market’… Premium vaccine competition outside of NIP

RSV, HPV, shingles high value-added vaccine market… Intense competition led by global big pharma (Graphics = Reporter Son Mi-kyung sssmk@) Attention is being paid to whether premium vaccines can be a way for pharmaceutical and bio companies to increase sales. Although there is no government support, companies are competing to secure market share in the … Read more